454426-80-3

Upstream product

• 4755-77-5 Ethyl oxalyl chloride 
• 1115-69-1 Ac-DL-Ala 

Downstream Products

• 224789-20-2 2-(2-Ethoxyphenyl)-5,7-dimethyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1101323-88-9 N-[1-(5-oxo-3-phenyl-4,5-dihydro-1,2,4-triazin-6-yl)ethyl]acetamide 
• 1101323-93-6 4-chloro-5,7-dimethyl-2-phenylimidazo[5,1-f][1,2,4]triazine 
• 1101323-91-4 5,7-dimethyl-2-phenylimidazo[5,1-f][1,2,4]triazin-4(3H)-one 
• 480427-03-0 N-{1-[3-(4-nitro-phenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]-ethyl}-acetamide 
• 644962-23-2 N-{1-[3-(3-nitro-phenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]-ethyl}-acetamide 
• 480426-73-1 N-{1-[3-(4-bromo-phenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]-ethyl}-acetamide 
• 439084-06-7 N-{1-[3-(3,4-dimethoxybenzyl)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl]ethyl}acetamide 

Relevant academic research and scientific papers

Synthetic method of vardenafil hydrochloride impurities

The invention discloses a synthetic method of vardenafil hydrochloride impurities, which relates to the technical field of pharmaceutical and chemical industry. The synthetic method comprises the following steps: taking alanine (A) as a raw material to react with acetic anhydride, generating 2-acetaminopropionic acid (B), enabling the 2-acetaminopropionic acid (B) to react with ethyl oxalyl monochloride, and generating a reaction product (C); enabling 2-ethoxybenzamidine hydrochloride (D) to react with hydrazine hydrate, generating a reaction product (E), enabling the reaction product (E) to react with the reaction product (C), and generating an impurity intermediate I (F); and enabling the impurity intermediate I (F) to generate an impurity intermediate II (G) under the effect of phosphorus oxychloride; performing sulfonation reaction on the impurity intermediate II (G) to generate a reaction product (H); and dropwise adding N-ethylpiperazine into the reaction product (H) to obtain a target product (I) 4-ethoxy-3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazole[5,1-f][1,2,4]-trizone-ketone) benzenesulfonic acid. The method is low in production cost, low in requirement on reaction conditions, favorable for the industrialized production and higher in purity of target products.

IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE

The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological di

SUBSTITUTED IMIDAZOTRIAZINES

The invention relates to novel substituted imidazotriazines, to methods for the production thereof, and to their use for producing medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative diseases, particularly Parkinson's disease and schizophrenia.

HETERO-CYCLICALY SUBSTITUTED IMIDAZOTRIAZINES

The invention relates to novel hetero-cyclically substituted imidazotriazines and a method for the production and use thereof for producing drugs which are used for curing and/or preventing cancers and neurodegenerative diseases, in particular Parkinson d

Substituted imidazotriazinones

The present invention relates to new substituted imidazotriazinones, processes for their preparation, and their use for the production of medicaments, in particular for improving perception, concentration power, learning power and/or memory power.

2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors

2-(Sulfamoyl-substituted phenyl)-3H-imidazo (5,1-f) (1,2,4) triazin-4-ones (I) are new. Imidazotriazinones of formula (I) and their salts, N-oxides and isomeric forms are new: R1 = H or 1-4C alkyl; R2 = 1-4C straight chain alkyl; R3, R4 = H, 2-8C alkenyl, 1-8C alkoxy or 1-10C alkyl (optionally interrupted by O and/or substituted by a very wide range of specific groups); or R3 or R4 = NR20R21, adamantyl, 2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl, sulfolanyl, hydroxy-sulfolanyl, 2-oxo-tetrahydrofuran-3-yl; or 3-8C cycloalkyl, 6-10C aryl or 5-7 membered heterocycle, all optionally substituted by specific groups; or NR3R4 = (a) optionally benzo-fused, saturated, partially unsaturated or unsaturated 5-7 membered heterocycle, optionally containing 1-3 of S, N, O and NR37 and optionally substituted by a very wide range of specific groups; or (b) a group of formula (i)-(iv); R20,R21 = H or 1-6C alkyl; R37 = H, OH, CHO, CF3, up to 4C acyl, up to 4C alkoxycarbonyl, 1-4C alkoxy, 1-6C alkyl (optionally substituted by specific groups) or -(CO)iE; i = 0 or 1; E = 3-7C cycloalkyl or benzyl; 6-10C aryl or 5- or 6-membered heteroaryl, both optionally substituted by specific groups ; or 5-methyl-1-oxo-2,1,3-oxadiazol-4-yl, N-methylpiperazino or morpholino; R5,R6 = H, 1-6C alkyl, OH or 1-6C alkoxy. The full definitions are given in the DEFINITIONS (Full Definitions) field. An Independent claim is included for the preparation of (I).